Although it has long been proposed that HDL is dysfunctional in type 1 diabetes (T1D), this hypothesis has not been formally tested in large cohorts using validated functional and biochemical HDL metrics. We therefore determined whether HDL particle concentration (HDL-P) and function differed between 187 middle-aged adults with childhood-onset T1D (mean age 51 years, T1D duration 43 years, 53% women) and 200 individuals with normal glucose tolerance (NGT) of similar age and sex distribution. HDL-P was assessed by calibrated ion mobility analysis. HDL function, i.e., serum HDL cholesterol efflux capacity, was quantified in J774 cells using a validated assay. Separate stepwise linear regression models were constructed for each HDL metric, allowing for T1D status and potential confounding factors, including HDL cholesterol (HDL-C). The presence of significant effect modification by sex was evaluated. After adjustment, the concentrations of total (T-HDL-P; β=-0.44, p=0.09) and medium-sized (M-HDL-P; β=-0.84, p<0.0001) HDL particles were lower in the T1D compared with the NGT group. In contrast, T1D status was not significantly associated with small (S-HDL-P) and large-sized (L-HDL-P) HDL-P. A significant sex by T1D status interaction term was observed for M-HDL-P (p=0.03), indicating that women had higher M-HDL-P only in NGT; M-HDL-P did not differ by sex in T1D. Moreover, a marginally significant sex by T1D status interaction was observed for L-HDL (p=0.08), suggesting that women had higher L-HDL-P only in T1D. Unexpectedly, serum HDL cholesterol efflux capacity was higher in the T1D compared with the NGT group (β=0.29, p<0.0001).

In conclusion, lower levels of T-HDL-P and M-HDL-P in T1D may explain in part the higher cardiovascular risk in T1D, as these metrics were recently shown to be associated with protection from vascular complications. The lack of a difference in M-HDL-P by sex in T1D may contribute to the loss of cardioprotection associated with female sex.

Disclosure

T. Costacou: None. T. Vaisar: Consultant; Self; AstraZeneca. J. Ju: None. K. Bornfeldt: None. T.J. Orchard: None. J. Heinecke: None.

Funding

National Institutes of Health (HL130153, DK34818)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.